AMP Begins Hypothetical Positions in Two Food Allergy Companies (DBVT & AIMT)


Amidst a down day in the biotech sector, AMP began two positions in food allergy companies DBV Technologies (NASDAQ: DBVT) and Aimmune Therapeutics (NASDAQ: AIMT).

Both companies have Phase 3 assets to treat peanut allergies and expect readouts from those trials by the end of 2017.

AMP purchased $12,500 worth of shares in both companies and now currently holds 583 and 289 shares of AIMT and DBVT respectively.

For more information see:

http://www.aimmune.com/pipeline/

https://www.dbv-technologies.com/en/viaskin-products


0 comments